Gene therapy and valacyclovir for recurrent brain tumors in young people
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new gene therapy that uses two special viruses and an oral antiviral drug (valacyclovir) to treat brain tumors that have come back in children and young adults. The therapy is given right after surgery to remove the tumor, with the goal of helping your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 3 to 39 years old with a malignant brain tumor that has come back after previous treatment.
- You are eligible for surgery to remove the tumor again.
- You weigh at least 22 pounds (10 kilograms).
- You are in generally good health without active infections or serious immune system problems.
- You are willing to use birth control if you or your partner can become pregnant (during and for 30 days after treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a “suicide gene” therapy delivered by a virus along with radiation for adults whose high-grade brain tumor has come back or grown again. The goal is to see if the treatment is safe and can help control the tumor.
This trial tests a virus-based treatment called MVR-C5252 for people whose high-grade glioma or glioblastoma has come back after standard therapy. The virus is injected directly into the tumor to try to kill cancer cells and boost the immune system. The goal is to see if it is safe and if it can shrink the tumor.
This trial tests a new gene therapy given directly into the brain tumor. It's for people with high-grade glioma, either newly diagnosed or after one recurrence, to see if it can help control the tumor.
This trial tests a modified herpes virus (M032) given directly into the brain tumor after standard radiation. The goal is to see if this virus can slow or stop the growth of diffuse midline glioma, a type of brain cancer.
This trial tests a two-part treatment: an injected virus (DB107-RRV) plus an oral medication (DB107-FC) for people whose high-grade glioma (a type of brain tumor) has come back. The virus is designed to deliver a gene that makes the tumor sensitive to the oral drug, which then helps kill the cancer cells.
This Phase 1/2 study tests whether combining an HSV-tk “gene switch” treatment, valacyclovir tablets, focused radiation (SBRT), and chemotherapy can help people with recurrent glioblastoma or anaplastic astrocytoma. It may help shrink tumors or slow growth after standard treatments have already been tried.
Hear when a new Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.